Genomic Valley Biotech Ltd
Genomic Valley Biotech Ltd (GVBL) last reported results for the quarter ended Jun 2026, with sales of ₹0.04 crore and net profit of ₹0.01 crore. The stock last traded at ₹30.2, a market capitalisation of ₹9.24 crore, on a P/E of 924. Over the past 52 weeks the stock has ranged between ₹20.1 and ₹38.2. Figures are as of 6 Oct 2026 and are not real time.
Genomic Valley Biotech Ltd share price and key metrics
- Current price
- ₹30.2
- Market cap
- ₹9.24 cr
- Stock P/E
- 924
- Book value
- ₹12.8
- ROE
- 0.77%
- ROCE
- 1.02%
- Dividend yield
- 0.00%
- 52w high / low
- 38.2/20.1
Metrics as of 6 Oct 2026. Not real time.
Track Genomic Valley Biotech Ltd
Cruxal reads every Genomic Valley Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Genomic Valley Biotech Ltd growth and returns
- 10 Years
- 9%
- 5 Years
- 5%
- 3 Years
- -54%
- TTM
- -72%
- 10 Years
- 8%
- 5 Years
- 15%
- 3 Years
- -68%
- TTM
- -96%
- 10 Years
- %
- 5 Years
- 5%
- 3 Years
- 8%
- 1 Year
- -8%
- 10 Years
- 2%
- 5 Years
- 5%
- 3 Years
- 4%
- Last Year
- 1%
Genomic Valley Biotech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.04 cr, down 55.6% from ₹0.09 cr a year earlier. Net profit was ₹0.01 cr, down 50.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.21 | 0.22 | 0.26 | 0.09 | 0.09 | 0.05 | 0.04 | 0.04 |
| Expenses | 0.07 | 0.06 | 0.26 | 0.06 | 0.09 | 0.04 | 0.04 | 0.02 |
| Operating profit | 0.14 | 0.16 | 0 | 0.03 | 0 | 0.01 | 0 | 0.02 |
| OPM % | 66.67% | 72.73% | 0.00% | 33.33% | 0.00% | 20.00% | 0.00% | 50.00% |
| Other income | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0.15 | 0.16 | 0 | 0.03 | 0 | 0.01 | 0 | 0.02 |
| Tax % | 0.00% | 0.00% | — | 0.00% | — | 0.00% | — | 0.00% |
| Net profit | 0.15 | 0.16 | -0.08 | 0.02 | 0 | 0.01 | -0.01 | 0.01 |
| EPS (₹) | 0.49 | 0.52 | -0.26 | 0.07 | 0.00 | 0.03 | -0.03 | 0.03 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Genomic Valley Biotech Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.27 | 0.22 |
| Operating profit | -0.04 | 0.1 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.04 | 0.03 |
| OPM % | -9.09% | 16.95% | 42.42% | 64.71% | -61.90% | -542.86% | 32.35% | 11.76% | 52.38% | 14.81% | 13.64% |
| Net profit | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.03 | 0.01 |
| EPS (₹) | -0.23 | 0.10 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.10 | 0.03 |
TTM is the trailing twelve months to the most recent quarter.
Genomic Valley Biotech Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves | 1.44 | 1.47 | 1.71 | 1.99 | 1.43 | -0.18 | 0.47 | 0.49 | 0.84 | 0.87 |
| Borrowings | 0.75 | 0.75 | 1.48 | 1.48 | 1.55 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other liabilities | 0.78 | 1.41 | 0.94 | 1.49 | 1.59 | 0.92 | 0.90 | 0.79 | 0.47 | 0.33 |
| Total liabilities | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.25 |
| Fixed assets | 3.63 | 4.12 | 4.31 | 4.47 | 5.86 | 1.75 | 0.00 | 0.00 | 0.01 | 0.00 |
| CWIP | 0.00 | 0.38 | 0.49 | 0.49 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Other assets | 2.39 | 2.18 | 2.38 | 3.05 | 1.27 | 2.04 | 4.42 | 4.31 | 4.35 | 4.25 |
| Total assets | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.25 |
As reported by the company. Total assets equal total liabilities by construction.
Genomic Valley Biotech Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.35 | 0.87 | -1.04 | 0.44 | 1.48 | -2.13 | -0.78 | -0.02 | 0.03 | -0.02 |
| Cash from investing | -0.31 | -0.91 | 0.37 | -0.47 | -1.58 | 3.67 | 1.52 | -0.02 | 0.01 | 0.00 |
| Cash from financing | 0.00 | 0.00 | 0.73 | 0.00 | 0.07 | -1.55 | -0.70 | 0.00 | 0.00 | 0.00 |
| Net cash flow | 0.04 | -0.04 | 0.06 | -0.04 | -0.03 | -0.01 | 0.04 | -0.04 | 0.04 | -0.02 |
| Free cash flow | -0.15 | -0.07 | -0.68 | -0.04 | -0.10 | 3.22 | 0.70 | -0.02 | 0.02 | -0.02 |
| CFO / operating profit | -875% | 870% | -248% | 80% | -1,138% | 561% | -89% | -100% | 27% | -25% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Genomic Valley Biotech Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -0.57% | 0.57% | 4.17% | 5.96% | -5.10% | -8.54% | 28.48% | 0.57% | 11.84% | 1.02% |
| Debtor days | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 960.30 | 3,136.30 |
| Inventory days | — | — | — | — | 0.00 | — | 0.00 | — | 486.67 | — |
| Days payable | — | — | — | — | — | — | — | — | 17.38 | — |
| Cash conversion cycle | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 1,429.58 | 3,136.30 |
| Working capital days | -514.32 | -804.24 | 55.30 | -176.06 | -1,251.43 | 4,849.29 | 221.42 | 4,530.29 | 916.85 | 3,176.85 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Genomic Valley Biotech Ltd shareholding pattern
Promoters held 46.06% at Jun 2026, down from 46.72% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.67% | 46.83% | 46.78% | 46.72% | 46.72% | 46.06% | 46.06% | 46.06% |
| Public | 45.33% | 53.16% | 53.20% | 53.28% | 53.29% | 53.94% | 53.94% | 53.94% |
| No. of shareholders | 2,128 | 2,497 | 2,504 | 2,460 | 2,459 | 2,522 | 2,481 | 2,448 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Genomic Valley Biotech Ltd corporate filings
- Certificate under Regulation 74 (5) of SEBI (DP) Regulation, 2018 for the quarter ended on 30th September, 2026.Company Updatelow impact
- Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find enclosed herewith intimation for closure of trading window.
Read the full analysis - Genomic Valley Biotech Limited receives ROC approval to extend AGM deadline to December 31, 2026Otherslow impact
Cruxal's analysis: Genomic Valley Biotech Limited has been granted a 3-month extension by the Registrar of…
Read the full analysis - Genomic Valley Biotech Limited Reports Q1 FY2027 Financial ResultsCompany Updatelow impact
Cruxal's analysis: Genomic Valley Biotech Limited has published its standalone unaudited financial results…
Read the full analysis - Genomic Valley Biotech Limited reports Q1 FY27 standalone net profit of 1.46 lakh on revenue of 3.80 lakhBoard Meetinglow impact
Cruxal's analysis: Genomic Valley Biotech Limited has released its standalone unaudited financial results…
Read the full analysis - Genomic Valley Biotech Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Genomic Valley Biotech Limited has issued a formal intimation regarding a Board of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.